These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26405578)

  • 1. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.
    Qiao J; Dey M; Chang AL; Kim JW; Miska J; Ling A; M Nettlebeck D; Han Y; Zhang L; Lesniak MS
    Oncoimmunology; 2015 Aug; 4(8):e1022302. PubMed ID: 26405578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
    Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
    Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
    Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.
    Qi Z; Long X; Liu J; Cheng P
    Front Cell Neurosci; 2022; 16():819363. PubMed ID: 36159398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.
    Ahn HM; Hong J; Yun CO
    Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
    Belcaid Z; Berrevoets C; Choi J; van Beelen E; Stavrakaki E; Pierson T; Kloezeman J; Routkevitch D; van der Kaaij M; van der Ploeg A; Mathios D; Sleijfer S; Dirven C; Lim M; Debets R; Lamfers MLM
    Neurooncol Adv; 2020; 2(1):vdaa011. PubMed ID: 32642679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
    Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
    Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
    Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
    Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.
    Kim JW; Miska J; Young JS; Rashidi A; Kane JR; Panek WK; Kanojia D; Han Y; Balyasnikova IV; Lesniak MS
    Mol Ther Oncolytics; 2017 Jun; 5():97-104. PubMed ID: 28573184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.
    Auffinger B; Ahmed AU; Lesniak MS
    Front Oncol; 2013; 3():32. PubMed ID: 23443138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma.
    Zhang Q; Zhang J; Tian Y; Wang J; Jin G; Liu F
    Virology; 2023 Oct; 587():109885. PubMed ID: 37738842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
    Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
    Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.
    Panek WK; Kane JR; Young JS; Rashidi A; Kim JW; Kanojia D; Lesniak MS
    Oncotarget; 2017 Oct; 8(51):89391-89405. PubMed ID: 29179527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.